neoadjuvant, immune checkpoint inhibitor, surrogate, overall survival
surrogate, Overall survival, objective response rate, major pathological response, pathological complete response, relapse-free survival
bone metastases, Bone-targeting agents, Skeletal-related events, Symptomatic skeletal events, Immunotherapy
NSCLC, brain metastases, immune checkpoint inhibitors, stereotactic radiotherapy